In generic drug development, every excipient decision matters—not just for performance, but for regulatory approval. One of the most underrated tools we have is the FDA Inactive Ingredient Database (IID). The IID isn’t just a list. It’s a strategic database that gives you regulatory confidence while selecting excipients. It contains excipients that are already approved…
In pharmaceutical development, what you know before you start determines how far—and how fast—you go. The Handbook of Pharmaceutical Generic Development underscores the literature search as the first strategic pillar of generic drug development. It’s not just academic—it’s operational intelligence. Here’s what a high-quality literature search accomplishes: Establishes the Regulatory Landscape Knowing the regulatory path…
In pharmaceutical development, understanding your Critical Quality Attributes (CQAs) is not just regulatory jargon — it’s the foundation of Quality by Design (QbD). According to ICH Q8(R2), a CQA is any physical, chemical, biological, or microbiological characteristic that must be controlled within an appropriate range to ensure the desired product quality. These attributes have a…
Once regulatory direction is clear, the next step is formulation development—the heart of generic product success. But remember, formulation is not just about blending ingredients. It’s a strategic and scientific process. The goal is not only to match the innovator product (RLD), but to ensure your formulation is bioequivalent, manufacturable, stable, and regulatory compliant. Here’s…
In generic drug development, technical skills alone are not enough. What truly ensures timely success is strong regulatory planning—right from Day 1. Before you even begin pre-formulation work or touch any excipient, you must sit with your Regulatory Affairs team and carefully plan how the product will be registered. This includes understanding FDA requirements, patent…
The 22 sections of an ANDA (Abbreviated New Drug Application) refer to the structured format used for submission to the USFDA, typically following the CTD (Common Technical Document) format. Here’s a simplified list based on how the “Handbook of Pharmaceutical Generic Development” and USFDA expectations outline it: Key Components of the 22 Sections (Non-CTD Format…
